One Kendall Square
Building 300, Suite 201
21 articles with AVROBIO
10/14/2019It was a busy week for clinical trial announcements. Here’s a look.
Investigational Therapy Designed to Engineer Patients’ Own Stem Cells to Produce Essential Protein
AVROBIO, Inc. announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan’s 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019.
AVROBIO, Inc. announced that members of its senior management team are scheduled to participate in five upcoming investor conferences.
AVROBIO, Inc. (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the appointment of Georgette Verdin as Chief Human Resources Officer (CHRO).
AVROBIO, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2018 Stock Option and Incentive Plan in accordance with NASDAQ Listing Rule 5635.
AVROBIO, Inc. reported financial results for the second quarter ended June 30, 2019 and provided a business update.
AVROBIO, Inc., a Phase 2 clinical-stage gene therapy company, announced that the Company will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 2:30 p.m. ET at the Parker New York Hotel in New York City.
AVROBIO, Inc., a Phase 2 clinical-stage gene therapy company, announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $18.50 per share.
AVROBIO, Inc. announced that it intends to offer and sell, subject to market and other conditions, $100.0 million of its common stock in an underwritten public offering.
AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease
AVROBIO, Inc. announced the first kidney biopsy result and additional positive data from two ongoing clinical trials of its AVR‑RD‑01 investigational gene therapy in Fabry disease.
AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease
The plato™ platform represents a significant advance towards a commercial-stage gene therapy solution designed to treat thousands of patients
AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
AVROBIO, Inc. announced the participation of its senior management in sessions at the Annual Meeting of the American Society of Gene and Cell Therapy.
AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
Introduced plato™ platform for worldwide gene therapy commercialization, to be incorporated in AVROBIO-sponsored clinical trials in 2019
AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
All patients with reported data exhibit AGA enzyme activity above the diagnostic range for males with classic Fabry disease after receiving AVR-RD-01, including at 22 months for Patient 1 in the Phase 1 study
Shares of Cambridge, Mass.-based Avrobio plunged more than 50 percent on Monday after the company provided an updated look at its gene therapy for Fabry disease that showed promise for the treatment, but also raised some concern for investors.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
6/22/2018Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.